Unfortunately, for operational reasons, NICE is unable to proceed with next week’s committee discussion of zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma.We will update about rescheduling this discussion